Welcome to our dedicated page for ATRS news (Ticker: ATRS), a resource for investors and traders seeking the latest updates and insights on ATRS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ATRS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ATRS's position in the market.
Antares Pharma (NASDAQ: ATRS) presented new data on testosterone enanthate for adolescent hypogonadal males at the Pediatric Endocrine Society 2021 Virtual Annual Meeting. The study, led by Dr. Maria Vogiatzi, utilized pharmacokinetic modeling from a Phase 2 trial of XYOSTED to demonstrate that a reduced frequency of subcutaneous testosterone administration could match testosterone exposure in normal adolescents. This suggests a potential new treatment avenue for a currently underserved population, though further clinical studies are needed for FDA approval.
Antares Pharma, a specialty pharmaceutical company, has announced that its CEO, Robert F. Apple, will participate in the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021. This virtual event allows the Company to engage with investors and discuss its innovative pharmaceutical products, primarily in urology and endocrinology. Antares Pharma's FDA-approved products include XYOSTED® and OTREXUP®.
The company has strategic alliances with major pharmaceutical firms, enhancing its market presence and future growth potential.
Antares Pharma (NASDAQ: ATRS) announced it will release its Q1 2021 financial results on May 6, 2021, before market opening. A conference call is scheduled for the same day at 8:30 AM ET, accessible via phone and a live webcast on their corporate website. The company specializes in pharmaceutical products targeting urology and endocrinology with a portfolio of approved products including XYOSTED® and NOCDURNA®. Investors should note potential impacts from COVID-19 and market acceptance of their offerings.
Antares Pharma (NASDAQ: ATRS) announced the appointment of Peter Richardson as Executive Vice President and Chief Medical Officer. Dr. Richardson brings over 25 years of pharmaceutical experience, overseeing research and development, clinical operations, and regulatory affairs. His track record includes successful approvals for over 20 marketed products.
CEO Robert Apple noted that Richardson's expertise will support the advancement of Antares' proprietary pipeline, particularly products ATRS-1901 and ATRS-1902. This leadership change aims to enhance growth opportunities for the company.
Antares Pharma, Inc. reported a record revenue of $149.6 million for the full year 2020, a 21% increase year-over-year. The company achieved a net income of $56.2 million, boosted by a significant tax benefit of $46.3 million. In Q4 2020, revenue was $44.1 million, with net income at $51.4 million. The company’s proprietary product XYOSTED drove sales, with guidance for 2021 revenue projected between $175 million and $200 million, indicating potential growth of 17% to 34%. Antares aims to expand its offerings with ongoing partnerships and upcoming product launches.
Antares Pharma (NASDAQ: ATRS) announced on February 24, 2021, that CEO Robert F. Apple will present at two upcoming virtual investor conferences. The Raymond James 42nd Annual Virtual Institutional Investors Conference will feature a fireside chat on March 3, 2021, at 3:50pm ET. Following that, Apple will host a fireside chat at the Cowen 41st Annual Virtual Healthcare Conference on March 4, 2021, at 9:10am ET. Live webcasts will be accessible on the company's website.
Antares Pharma, Inc. (NASDAQ: ATRS) announced it will release its fourth quarter and full-year 2020 financial results on March 2, 2021, before market open. A conference call will follow at 8:30 am ET, with dial-in numbers provided for domestic and international callers. Antares Pharma develops self-administered injectable products and has FDA-approved products like XYOSTED® and OTREXUP®. The company emphasizes its strategic alliances with major pharmaceutical firms such as Teva and Pfizer, and notes risks tied to its future performance.
Antares Pharma, Inc. (NASDAQ: ATRS) announced that CEO Robert F. Apple will host investor meetings at the SVB Leerink 10th Annual Virtual Global Healthcare Conference from February 22-26, 2021. The company specializes in self-administered injectable products using advanced drug delivery technology. Antares has a diverse product portfolio, including FDA-approved XYOSTED® and OTREXUP®, and significant partnerships with industry leaders like Teva and Pfizer. The press release also highlights potential risks affecting future performance, including market acceptance and COVID-19 impacts.
Antares Pharma announces an updated revenue guidance for 2020 and 2021. For 2020, expected revenue ranges from $145 to $150 million, revised from $135 to $155 million. Looking ahead to 2021, revenue is projected between $175 to $200 million, anticipating 19-36% growth year-over-year. This outlook assumes no major disruptions from the COVID-19 pandemic and reflects strong market demand for XYOSTED and Teva’s EpiPen. The company also aims for a successful relaunch of NOCDURNA and hopes to capitalize on potential FDA approval for Forteo.
Antares Pharma, a pharmaceutical technology company listed on NASDAQ under the ticker ATRS, announced that its CEO, Robert F. Apple, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. This event includes a pre-recorded webcast of a fireside chat, accessible in the 'For Investors' section of their website. Antares specializes in self-administered injectable products and has significant partnerships with leading pharmaceutical firms, including Teva and Pfizer. The company has several FDA-approved products in its portfolio.
FAQ
What is the market cap of ATRS (ATRS)?
